ABBV-744是一種對BDII具有選擇性的BET bromodomain抑制劑,可抑制BRD2、BRD3和BRD4。它可進一步研究用于治療急性髓細胞性白血病和癌癥。
此產品僅用于科學研究,我們不為任何個人用途提供產品和服務
ABBV-744 is a BDII-selective BET bromodomain inhibitor that is being investigated to treat AML and metastic castration-resistant prostate cancer.
Reference:
[1]. FIDANZE, Steven D., et al. BROMODOMAIN INHIBITORS. WO 2017177955 A1.
